SCHEMBL20375533

SCHEMBL20375533

COC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
DGAT1 O75907 1/20 0.34
ACLY P53396 1/20 0.34
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
CES2 O00748 2/20 0.32
TSHR P16473 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
ACAT1 P24752 1/20 0.32
SOAT1 P35610 1/20 0.32
THRB P10828 1/20 0.32
PKM P14618 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.31
PPARA Q07869 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6256870 0.98 CYP4F2 (0.42) CYP4F2CYP4A11DGAT1ACLYACACB
SCHEMBL5527551 0.98 CYP4F2 (0.46) CYP4F2CYP4A11DGAT1ACLYACACB
SCHEMBL22016456 0.93 ACLY (0.46) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL6258518 0.92 CYP4F2 (0.39) CYP4F2CYP4A11DGAT1ACLYTSHR
SCHEMBL8057594 0.91 ACLY (0.49) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL27438732 0.91 ACLY (0.49) CYP4F2CYP4A11ACLYACACBACACA
SCHEMBL6286840 0.88 CYP4F2 (0.35) CYP4F2CYP4A11DGAT1TSHR
SCHEMBL7947550 0.88 CYP4F2 (0.43) CYP4F2CYP4A11DGAT1ACLYACACB
SCHEMBL16368797 0.86 CYP4F2 (0.47) CYP4F2CYP4A11DGAT1ACLYACACB
SCHEMBL6258085 0.83 DGAT1 (0.37) CYP4F2CYP4A11DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227285-B2 Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers GEMPHIRE THERAPEUTICS INC. (US) 2019-03-12 US disclosed
US-20180194713-A1 PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS GEMPHIRE THERAPEUTICS INC. 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194713-A1 PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS DGKI, DGKA, SQLE CYP4F2 129/4885CYP4A11 250/4885DGAT1 35/4885
US-10227285-B2 Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers DGKI, DGKA, SQLE CYP4F2 129/4885CYP4A11 250/4885DGAT1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.